Rationale and Design of MILES-3 and MILES-4 Studies: Two Randomized Phase 3 Trials Comparing Single-Agent Chemotherapy Versus Cisplatin-Based Doublets in Elderly Patients With Advanced Non--Small-Cell Lung Cancer

Gridelli, Cesare; Rossi, Antonio; Di Maio, Massimo; Leo, Silvana; Filipazzi, Virginio; Favaretto, Adolfo G.; Burgio, Marco A.; Cinieri, Saverio; Bianco, Roberto; Ciardiello, Fortunato; Cavanna, Luigi; Bordonaro, Roberto; Costanzo, Raffaele; Sandomenico, Claudia; Gallo, Ciro; Perrone, Francesco; Morabito, Alessandro
March 2014
Clinical Lung Cancer;Mar2014, Vol. 15 Issue 2, p166
Academic Journal
No abstract available.


Related Articles

  • Chemotherapy of Non-small Cell Lung Cancer in Elderly Patients. Gridelli, C.; Maione, P.; Colantuoni, G.; Rossi, A. // Current Medicinal Chemistry;Aug2002, Vol. 9 Issue 16, p1487 

    Non-small cell lung cancer (NSCLC) may be considered typical of advanced age. More than 50% of NSCLC patients are diagnosed over the age of 65 and approximately one-third of all patients with non-small cell lung cancer (NSCLC) are over the age of 70. Elderly patients tolerate chemotherapy poorly...

  • Lung Cancer.  // Current Medical Literature: Respiratory Medicine;2009, Vol. 23 Issue 3, p74 

    The article summarizes studies related to lung cancer. The study "Cetuximab Plus Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer (FLEX): An Open-Label Randomised Phase III Trial," by R. Pirker et al assessed patients with stage IIIB or stage IV non-small-cell lung cancer. It...

  • Randomized Phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. Halmos, Balazs // Current Medical Literature: Lung Cancer;2013, Vol. 7 Issue 2, p49 

    The article discusses research on the treatment of advanced non-small-cell lung cancer. It references the study "Randomized Phase III Trial of Single-Agent Pemetrexed Versus Carboplatin and Pemetrexed in Patients With Advanced Non-Small-Cell Lung Cancer and Eastern Cooperative Oncology Group...

  • Randomized, Prospective Trial of Customized Neoadjuvant versus Standard Chemotherapy Gets Underway. Buckley, Rita // MD Conference Express;Jun2014, Vol. 14 Issue 3, p14 

    The first prospective, multicenter, randomized Phase 2 study to test the use of customized chemotherapy (CT) in locally advanced stage IIIA (N2) non—small cell lung cancer (NSCLC) is currently recruiting patients. The rationale and design of the Customized Neoadjuvant Versus Standard...

  • A Meta Analysis of Doublets Versus Single-agent Chemotherapy for Elderly Patients with Advanced Non-small Cell Lung Cancer. Chong'an XU; Ziyou CHANG; Xiaojie WANG; Lin LI; Haiyan QI; Yan LIU // Chinese Journal of Lung Cancer;Jun2012, Vol. 15 Issue 6, p361 

    Background and objective It remains disputed whether doublets are more effective than single-agent chemotherapy for elderly patients with advanced non-small cell lung cancer (NSCLC). The aim of this study is to evaluate the efficacy and safety of doublets and single-agent chemotherapy for...

  • Chemotherapy.  // Current Medical Literature: Lung Cancer;2008, Vol. 2 Issue 1, p10 

    The article discusses several studies on chemotherapy. A. Rajeswaran and colleagues study the efficacy and toxicity of platinum-based chemotherapy regimens compared with platinum-free therapies in the first-line treatment of advanced non-small cell lung carcinoma (NSCLC). A study by R. Lilenbaum...

  • Sequential, Alternating, and Maintenance/Consolidation Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Review of the Literature. Grossi, Francesco; Aita, Marianna; Follador, Alessandro; Defferrari, Carlotta; Brianti, Annalisa; Sinaccio, Graziella; Belvedere, Ornella // Oncologist;Apr2007, Vol. 12 Issue 4, p451 

    A platinum-based doublet with a third-generation agent (paclitaxel, vinorelbine, gemcitabine, docetaxel) represents the standard first-line treatment for advanced non-small cell lung cancer patients with good performance status (PS). Traditional chemotherapy provides response rates of 20%-40%...

  • Optimizing First-Line Treatment Options for Patients with Advanced NSCLC. Heather Wakelee // Oncologist;Oct2005, Vol. 10 Issue 9, p1 

    The median survival time for advanced non-small cell lung cancer (NSCLC) remains poor, despite years of research into new chemotherapy combinations. Platinum-based chemotherapy has long been the standard of care for the initial treatment of advanced NSCLC. While no one particular platinum-based...

  • Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer. Bunn Jr., Paul A.; Lilenbaum, Rogerio // JNCI: Journal of the National Cancer Institute;3/5/2003, Vol. 95 Issue 5, p341 

    Editorial. Discusses whether chemotherapy should be offered for elderly patients with advanced non-small cell lung cancer (NSCLC). Types of analyses used to provide evidence to support the claim that elderly patients with NSCLC should be offered chemotherapy; Comparison between single-agent...

  • Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non-small-cell lung cancer. Sakakibara, T.; Inoue, A.; Sugawara, S.; Maemondo, M.; Ishida, T.; Usui, K.; Abe, T.; Kanbe, M.; Watanabe, H.; Saijo, Y.; Nukiwa, T. // Annals of Oncology;Apr2010, Vol. 21 Issue 4, p795 

    Background: The optimal platinum doublet regimen in elderly patients with non-small-cell lung cancer (NSCLC) is still uncertain. We conducted a randomized phase II study to compare the efficacy and safety of weekly paclitaxel combined with carboplatin with those of the standard schedule.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics